Medication that has been a lifeline for patients with uncontrollable diabetes is now slowly shifting from injections to pills, a move that could fundamentally alter treatment for the disease – and who can access it.
uncertain
who → shift → it
This shift could also affect the treatment of obesity, a long misunderstood condition once associated with overeating and laziness, rather than the metabolic disorder it is now recognised as.
uncertain
it → affect → overeating
Recommended Stories
list of 4 items- list 1 of 4Can GLP-1 drugs like Ozempic cause vision loss?
asserted
drugs → cause → loss
What we know about the risk
- list 2 of 4Sweet scoop:
asserted
know → know → risk
4With every rainfall, Gaza risks losing access to power and healthcare
GLP-1 (glucagon-like peptide-1) receptor agonists therapy isn’t new.
asserted
therapy → risk → power
The first FDA-approved drug, Exenatide, hit the market in 2005 and was followed by Liraglutide in 2009, which was seen as a revolutionary alternative to insulin.
asserted
which → approve → insulin
But the market has until recently been dominated by weekly injections like Ozempic and Wegovy (semaglutide), and Mounjaro (tirzepatide).
asserted
market → dominate → Ozempic
These drugs have also proved successful for weight loss.
asserted
drugs → prove → loss
Now, once-daily oral GLP pills are emerging as an alternative, especially for the diabetes-stricken Global South.
asserted
pills → emerge → South
Oral once-daily pills of the same wonder drug could make access more affordable, and less reliant on the cold chain that GLP-1 injections and insulin depend on – and that are harder to secure in emerging economies.
uncertain
that → make → economies
Why this matters
asserted
this → matter → ?
One in nine people in the world between the ages of 20-79 lives with diabetes, and one in eight people globally is obese.
asserted
people → live → diabetes
The GLP injections come with a high price tag and are often not covered by insurance companies, which treat them as an elective drug.
asserted
which → come → drug
In the United States, Eli Lily’s Mounjaro costs about $500 for a month’s worth of doses; in the UK, about 199 pounds ($264); and in Saudi Arabia, 1,261 riyals ($336).
asserted
Mounjaro → cost → Arabia
In India, the brand is locally manufactured and available at 14,766 rupees ($157).
asserted
brand → manufacture → rupees
In Pakistan, the imported Mounjaro is a whopping 220,000 rupees ($723), while the locally manufactured Tirzepatide from Getz Pharma costs 17,000 rupees ($61).
asserted
Tirzepatide → import → rupees
While pills are usually taken once a day, injections are once per week.
asserted
injections → take → week
Pakistan has the highest diabetes prevalence in the world – 31.4 percent of its population suffer from the disease – followed by the Marshall Islands (25.7 percent) and Kuwait (25.6 percent).
asserted
percent → have → Islands
Many other Middle Eastern countries rank among nations with the highest diabetes prevalence.
asserted
countries → rank → prevalence
For many countries in the Global South, the relative affordability of oral GLP drugs, where the locally manufactured oral semaglutide is about $18 for a 30-day supply, could make them more accessible for diabetes and obesity patients, remove the need for refrigeration and make rural distribution easier.
Dr Zakir Alavi is an endocrinologist in Karachi, Pakistan and has been treating patients with diabetes and obesity for nearly 30 years.
uncertain
Alavi → manufacture → years
We have, on one hand, childhood malnutrition, underweight, and stunted growth.
asserted
We → have → malnutrition
On the other hand, we have childhood and adult obesity,” said Alavi.
asserted
Alavi → have → obesity
“And surprisingly, there is at least some element in the adult and childhood obesity which can be linked to a malnourished mother, and an underweight, premature baby.”
asserted
which → be → mother
Malnutrition during pregnancy can lead to low birth weight, and babies born small who gain weight rapidly in infancy face a higher risk of childhood obesity, according to doctors.
uncertain
who → lead → doctors
Alavi said GLP drugs – whether the injectables or pills – have revolutionised the management of type 2 diabetes and obesity.
asserted
drugs → say → diabetes
They not only help type 2 diabetes patients manage their weight, but can also help non-diabetics tackle obesity, improving cardiac and renal outcomes, liver disease, obstructive sleep apnea and osteoarthritis.
“They can be used for management of all these things when weight reduction is important, or sugar control is important, or both,” he said.
asserted
he → help → things
Malik has been at the front line of helping patients with diabetes and obesity, and he echoed Alavi’s views.
asserted
he → help → views
“We looked at how much weight you need to lose to cure diabetes, the magic number seemed to come in at around 15kg, at least,” he said, speaking of research on the subject.
asserted
he → look → subject
How was GLP therapy discovered?
asserted
therapy → discover → ?
Jens Juul Holst is one of the central scientists behind the GLP revolution that has given millions around the world a way to live with diabetes and, for those struggling with obesity, a chance to reclaim their bodies.
asserted
that → give → bodies
A professor, physician and physiologist, Holst lives in Copenhagen and began his journey with gut hormones in the 1970s.
asserted
Holst → live → 1970s
“When we discovered this, what we found was an insulin-releasing peptide from the gut,” Holst told Al Jazeera.
asserted
Holst → discover → Jazeera
“We were interested in what regulates insulin secretion, and that was as a physiological mechanism because we had some people who were developing too low blood glucose levels, [which is called] hypoglycemia, and we were looking for a peptide that could create insulin release stimulation and then be responsible for the low glucose levels.”
uncertain
that → regulate → levels
He says reactive hypoglycemia, which patients experience after certain operations like bariatric surgery, explains how the GLP molecule works.
asserted
molecule → say → surgery
Eventually, his team discovered that the molecule plays a role not only in insulin release and secretion, but also helps regulate appetite and food intake.
asserted
molecule → discover → appetite
“The discovery of that was actually perhaps even more exciting than the discovery of its insulin-releasing activities,” Holst said, the excitement in his voice rising.
asserted
excitement → release → voice
“And then, the big day really was when we were able to infuse people with diabetes with this new peptide and see what happened.”
asserted
what → infuse → peptide
They found that an intravenous infusion of GLP-1 “would normalise blood glucose levels completely in people with long-standing, problematic type 2 diabetes and this happened in the course of four hours,” he said.
asserted
he → find → hours
“From then on, we knew that we were really onto something big.”
asserted
we → know → something
Holst and his team’s discovery led to what is now known as semaglutide, which paved the way for another drug, tirzepatide, and a third drug called retatrutide that is currently undergoing trials with a potential release in 2027.
asserted
that → lead → 2027
…and 32 more, not listed.